StocksMedium•13 October 2026•
1 min read
Biomea Fusion Announces Positive Phase 1 Results for Oral Weight-Loss Drug BMF-650
Key Facts
1Biomea Fusion announced positive Phase 1 clinical trial results for BMF-650, its oral small-molecule GLP-1 receptor agonist.
2The drug demonstrated consistent weight reduction across five multiple ascending dose cohorts over a four-week period.
Biomea Fusion announced positive Phase 1 clinical trial results for BMF-650, its investigational oral small-molecule GLP-1 receptor agonist for weight loss. According to a company statement released via GlobeNewswire, the drug demonstrated consistent weight reduction across five multiple ascending dose cohorts over a four-week period.
BMEA closed at $1.36 on October 12, 2026, with the stock trading between a day low of $1.36 and a high of $1.46 during that session. The company is developing the candidate as a next-generation oral alternative to injectable treatments to compete in the high-growth GLP-1 and metabolic disease market.